Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.64 |
| ▸ | MC4R | P32245 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14407770 | 1.00 | SIGMAR1 (0.69) | SIGMAR1KDM4EKMT2AMEN1HRH3 | |
| SCHEMBL24317312 | 0.93 | KDM4E (0.60) | SIGMAR1KDM4EKMT2AMEN1HRH3 | |
| SCHEMBL12205470 | 0.93 | KDM4E (0.60) | SIGMAR1KDM4EKMT2AMEN1HRH3 | |
| SCHEMBL24316252 | 0.89 | SIGMAR1 (0.59) | SIGMAR1KDM4EKMT2AMEN1HRH3 | |
| SCHEMBL6742979 | 0.89 | SIGMAR1 (0.69) | SIGMAR1KDM4EKMT2AMEN1HRH3 | |
| SCHEMBL11611819 | 0.87 | SIGMAR1 (0.67) | SIGMAR1KDM4EKMT2AMEN1MC4R | |
| SCHEMBL23384237 | 0.86 | HRH3 (0.59) | SIGMAR1KDM4EKMT2AMEN1HRH3 | |
| SCHEMBL18712996 | 0.85 | SIGMAR1 (0.64) | SIGMAR1KDM4EKMT2AMEN1HRH3 | |
| SCHEMBL3260289 | 0.85 | SIGMAR1 (0.64) | SIGMAR1KDM4EKMT2AMEN1HRH3 | |
| SCHEMBL16226120 | 0.84 | CYP2D6 (0.69) | SIGMAR1KDM4EKMT2AMEN1MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240066029-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240018119-A1 | CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | TRINEURO (KR) | 2024-01-18 | — | — | US | disclosed |
| US-20240018119-A1 | CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | TRINEURO (KR) | 2024-01-18 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-11827641-B2 | Toll-like receptor antagonist compounds and methods of use | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827641-B2 | Toll-like receptor antagonist compounds and methods of use | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| EP-4273143-A1 | DERIVATIVE OF 2,5-DIKETOPIPERAZINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Dalian WZ Probiotics AD Health Co., Ltd (CN) | 2023-11-08 | — | — | EP | disclosed |
| US-20230302030-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPase | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CA) | 2023-09-28 | — | — | US | disclosed |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070010452-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-01-11 | — | — | US | disclosed |
| US-7157420-B2 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157420-B2 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20050085506-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION AND PHARMACOPEIA, INC. | 2005-04-21 | — | — | US | disclosed |
| US-20040097560-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | THE PROCTER & GAMBLE COMPANY | 2004-05-20 | — | — | US | disclosed |
| US-20040072849-A1 | Dioxanes and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-04-15 | — | — | US | disclosed |
| US-20040072849-A1 | Dioxanes and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-04-15 | — | — | US | disclosed |
| EP-0650171-B1 | Insulating articles with high surface electrical resistivity and high flame resistance | BASELL POLIOLEFINE SPA (IT) | 2002-09-25 | — | — | EP | disclosed |
| EP-0650171-A2 | Insulating articles with high surface electrical resistivity and high flame resistance | MONTELL NORTH AMERICA INC. (US) | 1995-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010452-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | METAP2, METAP1, DNPEP | SIGMAR1 4848/4885KDM4E 1216/4885KMT2A 446/4885 |
| US-20040097560-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | IL17A, CYP51A1, CD4 | SIGMAR1 1452/4885KDM4E 3566/4885KMT2A 3194/4885 |
| US-11827641-B2 | Toll-like receptor antagonist compounds and methods of use | TLR7, TLR9, TLR1 | SIGMAR1 376/4885KDM4E 1755/4885KMT2A 1145/4885 |
| US-20230302030-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPase | RAN, RANBP1, GDI2 | SIGMAR1 2357/4885KDM4E 4606/4885KMT2A 4807/4885 |
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | SIGMAR1 4116/4885KDM4E 1333/4885KMT2A 1750/4885 |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | TNNI3, IDH2, GLS | SIGMAR1 3790/4885KDM4E 2660/4885KMT2A 3200/4885 |
| US-20040072849-A1 | Dioxanes and uses thereof | UTS2R, HDAC5, AMDHD2 | SIGMAR1 3590/4885KDM4E 164/4885KMT2A 178/4885 |
| US-20240018119-A1 | CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | MAOA, DRD2, MAOB | SIGMAR1 288/4885KDM4E 693/4885KMT2A 469/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | SIGMAR1 3709/4885KDM4E 791/4885KMT2A 1574/4885 |
| US-20050085506-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | SIGMAR1 391/4885KDM4E 2865/4885KMT2A 2232/4885 |
| US-20240066029-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | SIGMAR1 3863/4885KDM4E 889/4885KMT2A 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.